BlackRock
PTGX icon

BlackRock’s Protagonist Therapeutics PTGX Stock Holding History

BlackRock’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26B Buy
10,307,837
+528,468
+5% +$55.2M 0.02% 638
2026
Q1 		$1.03B Buy
9,779,369
+63,370
+0.7% +$5.61M 0.02% 682
2025
Q4 		$849M Buy
9,715,999
+311,767
+3% +$25.5M 0.01% 767
2025
Q3 		$625M Sell
9,404,232
-226,109
-2% -$12.9M 0.01% 937
2025
Q2 		$532M Sell
9,630,341
-106,426
-1% -$5.11M 0.01% 1015
2025
Q1 		$471M Sell
9,736,767
-147,850
-1% -$6.2M 0.01% 1090
2024
Q4 		$382M Sell
9,884,617
-339,678
-3% -$14.8M 0.01% 1260
2024
Q3 		$460M Buy
10,224,295
+4,466,183
+78% +$180M 0.01% 1141
2024
Q2 		$200M Buy
5,758,112
+188,627
+3% +$5.52M ﹤0.01% 1621
2024
Q1 		$161M Buy
5,569,485
+25,583
+0.5% +$696K ﹤0.01% 1780
2023
Q4 		$127M Buy
5,543,902
+314,477
+6% +$5.5M ﹤0.01% 1942
2023
Q3 		$87.2M Buy
5,229,425
+220,152
+4% +$4.27M ﹤0.01% 2069
2023
Q2 		$138M Buy
5,009,273
+607,056
+14% +$15.2M ﹤0.01% 1830
2023
Q1 		$101M Buy
4,402,217
+750,060
+21% +$12.6M ﹤0.01% 2009
2022
Q4 		$39.8M Buy
3,652,157
+189,773
+5% +$1.6M ﹤0.01% 2622
2022
Q3 		$29.2M Buy
3,462,384
+7,468
+0.2% +$70.7K ﹤0.01% 2818
2022
Q2 		$27.3M Buy
3,454,916
+208,742
+6% +$2.52M ﹤0.01% 2908
2022
Q1 		$76.9M Sell
3,246,174
-35,462
-1% -$999K ﹤0.01% 2307
2021
Q4 		$112M Buy
3,281,636
+82,140
+3% +$2.6M ﹤0.01% 2144
2021
Q3 		$56.7M Buy
3,199,496
+158,955
+5% +$6.78M ﹤0.01% 2587
2021
Q2 		$136M Buy
3,040,541
+38,912
+1% +$1.28M ﹤0.01% 2059
2021
Q1 		$77.7M Buy
3,001,629
+409,918
+16% +$10.4M ﹤0.01% 2337
2020
Q4 		$52.2M Buy
2,591,711
+135,734
+6% +$2.92M ﹤0.01% 2441
2020
Q3 		$48M Buy
2,455,977
+414,517
+20% +$7.78M ﹤0.01% 2332
2020
Q2 		$36.1M Buy
2,041,460
+484,004
+31% +$6.07M ﹤0.01% 2440
2020
Q1 		$11M Sell
1,557,456
-4,501
-0.3% -$33.7K ﹤0.01% 2944
2019
Q4 		$11M Buy
1,561,957
+478,755
+44% +$4.75M ﹤0.01% 3199
2019
Q3 		$13M Buy
1,083,202
+65,781
+6% +$829K ﹤0.01% 3076
2019
Q2 		$12.3M Buy
1,017,421
+743,632
+272% +$8.22M ﹤0.01% 3132
2019
Q1 		$3.44M Buy
273,789
+13,241
+5% +$117K ﹤0.01% 3541
2018
Q4 		$1.75M Buy
260,548
+21,126
+9% +$168K ﹤0.01% 3723
2018
Q3 		$2.46M Sell
239,422
-14,613
-6% -$126K ﹤0.01% 3700
2018
Q2 		$1.71M Sell
254,035
-433,125
-63% -$3.33M ﹤0.01% 3788
2018
Q1 		$5.9M Buy
687,160
+192,632
+39% +$3.63M ﹤0.01% 3367
2017
Q4 		$10.3M Buy
494,528
+47,003
+11% +$834K ﹤0.01% 3131
2017
Q3 		$7.91M Buy
447,525
+16,059
+4% +$222K ﹤0.01% 3300
2017
Q2 		$4.88M Buy
431,466
+85,821
+25% +$918K ﹤0.01% 3478
2017
Q1 		$4.43M Buy
345,645
+345,383
+131,826% +$5.57M ﹤0.01% 3414
2016
Q4 		$6K Buy
+262
New +$5.84K ﹤0.01% 3499

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock's PTGX Position: Q2 2026 in Review

BlackRock increased its Protagonist Therapeutics (PTGX) stake by 5.4% in Q2 2026, buying an estimated $55.2M and bringing the position to 10,307,837 shares worth $1.26B. The position accounts for 0.02% of the portfolio, ranked #638.

BlackRock first reported a position in PTGX in Q4 2016 and has held it in 39 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • BlackRock held 10,307,837 shares of Protagonist Therapeutics worth $1.26B as of Q2 2026.
  • BlackRock bought 528,468 Protagonist Therapeutics shares in Q2 2026, an estimated $55.2M.
  • Protagonist Therapeutics made up 0.02% of BlackRock's portfolio in Q2 2026, its #638 holding.
  • BlackRock first reported a position in Protagonist Therapeutics in Q4 2016 and has held it in 39 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.